# Treatment Recap for CNS Lymphoma - March 3, 2025

---

## MRI Findings (2/20/2025)
- **Significant tumor progression** in the right hemisphere.
- Enhancing lesion in the **right periatrial white matter** grew from 0.9 x 0.5 cm to **3.0 x 1.5 cm**.
- **Right temporal lesion** grew from 1.3 x 0.7 cm to **4.8 x 2.7 cm**.
- Extensive **vasogenic edema**, **mass effect**, and **0.5 cm midline shift**.
- Consistent with **lymphoma progression** despite treatment.
- **Right lateral ventricle compressed**, with enlargement of the left lateral ventricle (suggesting developing hydrocephalus).

---

## Why is HD-MTX Failing?
| **Reason** | **Explanation** |
|---|---|
| **Intrinsic resistance** | Tumor pumps out methotrexate or lacks folate transporters. |
| **BBB issues** | Methotrexate may not reach some tumor sites. |
| **High tumor burden** | Fast growth outpaces drug effect. |
| **Pharmacokinetics** | Drug clearance too fast or levels too low. |
| **Acquired resistance** | Tumor evolves to resist methotrexate. |
| **Lack of combination** | MTX works better with cytarabine or rituximab. |

---

## Treatment Options (Full List)

### 1. Standard Frontline
- **HD-MTX ± Rituximab**
- **R-MPV** (Rituximab, Methotrexate, Procarbazine, Vincristine)
- **MATRix** (Methotrexate, Cytarabine, Thiotepa, Rituximab)

### 2. Salvage Therapy (If HD-MTX Fails)
- **Ibrutinib ± Chemo** (BTK Inhibitor)
- **Lenalidomide ± Rituximab** (R2 Regimen)
- **Pomalidomide** (next-gen Revlimid)
- **Temozolomide** (bridge therapy)
- **Hyper-CVAD ± intrathecal chemo (for systemic + CNS disease)**
- **Autologous Stem Cell Transplant (ASCT)** (if chemo-sensitive)

### 3. Intrathecal Options (for leptomeningeal spread)
- **Intrathecal Methotrexate**
- **Intrathecal Cytarabine**
- **Intrathecal Rituximab**

### 4. Radiation Options
- **Stereotactic Radiosurgery (SRS)** – precise, for focal lesions
- **Whole Brain Radiation (WBRT)** – for diffuse disease (higher cognitive risk)

### 5. Experimental/Targeted Therapies
- **CAR-T (CD19-directed)** – in trials for refractory cases
- **Venetoclax** (BCL-2 inhibitor)
- **Checkpoint Inhibitors (PD-1 blockade)** – Nivolumab, Pembrolizumab

### 6. Supportive/Palliative
- **Dexamethasone** – reduces edema & mass effect
- **CSF Shunting** – for hydrocephalus (ventriculoperitoneal shunt)
- **Seizure and Pain Management**

---

## Comparison: SRS vs. WBRT

| Feature | **SRS** | **WBRT** |
|---|---|---|
| **Target** | Specific lesions | Entire brain |
| **Sessions** | 1–5 | 10–15 |
| **Cognitive Risk** | Low | High |
| **Best for** | Local control | Diffuse disease |
| **Radiation Necrosis Risk** | Moderate | Higher |

---

## Revlimid (Lenalidomide) Summary

| Feature | **Details** |
|---|---|
| **Mechanism** | Immunomodulator + direct anti-tumor effect |
| **BBB Penetration** | Excellent |
| **Use** | Relapsed/refractory CNS lymphoma |
| **Combination** | Often with Rituximab (R2) |
| **Dosing** | 10–25 mg PO x 21 days per 28-day cycle |
| **Key Risks** | Blood clots, low blood counts, fatigue, neuropathy |

---

## Comparison: Salvage Therapies

| Treatment | Best For | Pros | Cons |
|---|---|---|---|
| **Lenalidomide** | Relapsed CNS lymphoma | Oral, BBB penetration, immunotherapy effect | Risk of clots, myelosuppression |
| **Ibrutinib** | BTK-driven CNS lymphoma | Targets B-cell receptor, works in resistant cases | Bleeding, infections |
| **CAR-T** | Refractory B-cell lymphoma | Potential long-term remission | CRS, neurotoxicity |
| **MATRix** | Salvage after HD-MTX failure | Strong response rates | High toxicity |

---

## Surgery?
| **Surgery Role** | **Details** |
|---|---|
| **Resection** | Rarely used (lymphoma is diffuse/infiltrative) |
| **Debulking** | Only if life-threatening mass effect |
| **Biopsy** | For diagnosis only (already done in this case) |

---

## Message from Dr. John Baird(Bulletized)

- **Limited experience with zanubrutinib for CNS lymphoma.**
- All published data on zanubrutinib are either:
    - **Small retrospective series** (example: https://doi.org/10.1200/JCO.2024.42.23_suppl.30)
    - **Ongoing phase I/II trials** (unpublished final results).
- **Ibrutinib has more prospective data in CNS lymphoma**, supported by multiple phase II studies.
- A **meta-analysis** of these studies can be found here: https://doi.org/10.1016/j.critrevonc.2024.104597
- While zanubrutinib may reach **higher concentrations in CSF**, it’s unclear whether **peak levels are the key factor** for BTK inhibitor (BTKi) effectiveness in DLBCL.
- **Zanubrutinib’s greater BTK specificity** usually means:
    - Fewer side effects than ibrutinib.
- After discussing with pharmacists:
    - **Insurance copay is $0 for either drug.**
    - Plan is to start **zanubrutinib 160 mg BID**.
- Zanubrutinib will be given **alongside the planned radiation** from Dr. Dandapani.
- After radiation, **consider adding a bispecific antibody** if disease control improves, to maximize remission chances.

---

## Summary of Recommendations
- **Current priority:** Evaluate for **salvage therapy** since HD-MTX is failing.
- **Options to discuss with oncology:**
    - **MATRix** (most intensive chemo option)
    - **Ibrutinib ± Lenalidomide** (targeted oral options)
    - **Consider intrathecal therapy if CSF involvement confirmed.**
    - **SRS for focal control if mass effect progresses.**
    - **Consider ASCT if remission can be re-established.**
    - **Discuss CAR-T if refractory to all else.**

---

## Suggested Questions for Oncology Team
1. **Why is HD-MTX failing?**
2. **Do we have molecular profiling to guide next steps?**
3. **Are we eligible for MATRix, R2, or Ibrutinib-based regimens?**
4. **Should intrathecal chemo be added now?**
5. **Should we pursue SRS for symptomatic areas?**
6. **Are we candidates for CAR-T clinical trials?**
7. **If no curative options remain, what is the best palliative approach?**

---

